Janus kinase 3 (JAK3)

Janus kinase 3 (JAK3) is a non-receptor tyrosine kinase that plays a critical role in the signaling pathway of Interleukin-2 (IL-2) and other cytokines sharing the common gamma chain (γc) receptor subunit, such as IL-4, IL-7, IL-9, IL-15, and IL-21. Unlike other JAK family members which are widely expressed, JAK3 expression is largely restricted to hematopoietic cells, particularly T-cells and Natural Killer (NK) cells, making it a highly specific target for immunosuppression. Upon IL-2 binding to its receptor, JAK3 associates with the γc chain and works in tandem with JAK1 to phosphorylate Signal Transducers and Activators of Transcription (STAT) proteins, primarily STAT5, which then translocate to the nucleus to drive lymphocyte proliferation and differentiation. Mutations in the JAK3 gene are a known cause of autosomal recessive severe combined immunodeficiency (SCID) due to the failure of T-cell development. In therapeutic contexts, JAK3 inhibitors are utilized or under investigation for the treatment of autoimmune disorders like rheumatoid arthritis and alopecia areata, as well as for preventing organ transplant rejection, by selectively dampening the immune response mediated by IL-2 signaling.

Other names

Janus kinase 3 (a protein tyrosine kinase)JAK-3Leukocyte Janus kinaseL-JAKTyrosine-protein kinase JAK3

Inhibition of the ATP-binding site of the kinase domain to prevent phosphorylation of STAT proteins, thereby blocking downstream gene transcription in response to IL-2 and other gamma-chain cytokines.